Search IconSearch
October 1, 2020/Cancer

Spine Stereotactic Radiosurgery Outcomes Among Adolescents and Young Adults With Metastatic Ewing Sarcoma and Osteosarcoma

Young patients with spinal tumors could be good candidates for radiosurgery, study suggests

650×450 Murray (1)

Spine stereotactic radiosurgery (SRS), which delivers a high dose of precisely targeted radiation to attack hard-to-treat spinal tumors, has become a common therapy for adults. However, even though adolescents and young adults have shown a high tolerance for aggressive treatment in the past, it has not yet become the standard of care for younger patients with metastatic sarcomas in the spine. Now early results from a study provide some of the first data showing that such patients are able to tolerate SRS for these types of cancers.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Treatment offers hope

The findings offer hope to a patient population that often comes to radiotherapy after multiple rounds of chemotherapy and prior radiation, making them at high risk for side effects, says Erin Murphy, MD, Director of Pediatric Radiation Oncology at Cleveland Clinic.

SRS offers major advantages for adolescent and young adult patients. It utilizes higher doses with multiple beams tightly aimed at the target site, reducing damage to surrounding tissue and minimizing radiation exposure. And since it can be delivered in just one to five sessions (fractions), it is far less disruptive to the patient’s school schedule and activities than conventional radiation therapy, which may require daily sessions for several weeks.

Treatment is more complex and requires greater planning. Patients must be immobilized in a specific position that can be reproduced for each session. During the session, treatment is guided by real-time imaging and patients must be immobilized in a specific position so that the position can be reproduced for each session.

Well tolerated, but be thoughtful about concurrent therapy

The new study, published in JNS Spine, looks at seven patients with metastatic Ewing sarcoma or osteosarcoma with a total of 11 spine lesions treated with SRS at Cleveland Clinic. Patients ranged in age from 15 to 26 years, with a median age of 20.3 years. Irradiated sites included the thoracic, lumbar and sacral spine, and the median dose delivered was 35 Gy in five fractions.

Within the study follow-up period, eight of the 11 treated lesions remained locally controlled for a median duration of 11.1 months. Treatment was well tolerated overall. While one patient developed grade 3 gastrointestinal toxicity, the patient’s treatment overlapped with a round of intense chemotherapy, which is a known risk factor for increased toxicity.

“The key takeaway is that patients actually tolerated these treatments really well, but you had to be very thoughtful about the concurrent therapies that are given,” Dr. Murphy says.

A secondary finding was that patients with larger tumors, paraspinal masses or epidural disease benefitted more from a fractionated course of treatment.

“These are small numbers and an early experience,” Dr. Murphy acknowledges, “but we thought it important to get it out there and share what we’ve learned from looking after these patients.”


Researchers are now conducting prospective trials to gather data on outcomes for adolescents and young adults being treated with radiosurgery for metastatic sarcomas. One question Dr. Murphy hopes to study is how SRS interacts with the patient’s own immune system to fight tumor cells. She also called for more clinical trials to better understand the right radiation dose and how radiosurgery can best be used in conjunction with other therapies.

“We can take a lot from our adult experience in doing spine radiosurgery, but we certainly know that these are different patient populations with different tumors and different chemotherapies and probably different immune responses,” she says. “So it’s both an exciting time but also a very challenging time, because there’s still a lot to learn.”


Related Articles

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Director of the Novel Cancer Therapeutics Center
May 2, 2024/Cancer/Innovations
Oncology Pharmacovigilance Clinic Expands Specialties

First-of-its-kind clinic for immune-related adverse events supports oncologists in managing severe side effects